Results 181 to 190 of about 774,543 (406)
Altered Activity of Palmitoylation-deficient and Isoprenylated Forms of the G Protein-coupled Receptor Kinase GRK6 [PDF]
R Loudon, Jeffrey Benovic
openalex +1 more source
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine+10 more
wiley +1 more source
Regulatory mechanisms that modulate signalling by G-protein-coupled receptors [PDF]
Stephan Böhm+2 more
openalex +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte+10 more
wiley +1 more source
Evidence for K+ channel control in Vicia guard cells coupled by G‐proteins to a 7TMS receptor mimetic [PDF]
F. Armstrong, Michael R. Blatt
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
K. Sriram, P. Insel
semanticscholar +1 more source
Advances in therapeutic peptides targeting G protein-coupled receptors
A. Davenport+4 more
semanticscholar +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source